# Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
Canonical URL: https://biopharmsignal.com/news/OCS/oculis-publishes-results-of-2026-annual-general-meeting-and-announces-election-of-gregory-d-perry-to-its-board-of-directors
Ticker: OCS
Company: Oculis
Source: Oculis
Published: 2026-05-14 20:05 EST
Original Source URL: https://investors.oculis.com
## Summary

ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 12:00 p.m.

## Article Body
ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 12:00 p.m.
## Recent Company News
- 2026-05-29 19:06 EST — [Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema](https://biopharmsignal.com/news/OCS/oculis-announces-topline-results-from-diamond-phase-3-trials-with-ocs-01-in-diabetic-macular-edema) — Source: Oculis
- 2026-05-14 20:05 EST — [Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors](https://biopharmsignal.com/news/OCS/oculis-publishes-results-of-2026-annual-general-meeting-and-announces-election-of-gregory-d-perry-to-its-board-of-directors) — Source: Oculis
- 2026-05-11 20:07 EST — [Oculis Reports Q1 2026 Financial Results and Provides Company Update](https://biopharmsignal.com/news/OCS/oculis-reports-q1-2026-financial-results-and-provides-company-update) — Source: Oculis
- 2026-05-07 08:58 EST — [Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial](https://biopharmsignal.com/news/OCS/oculis-announces-agreement-with-fda-on-a-special-protocol-assessment-spa-for-optic-neuritis-registrational-trial) — Source: Oculis
- 2026-05-05 08:00 EST — [Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting](https://biopharmsignal.com/news/OCS/latest-findings-from-dme-aware-delphi-study-presented-at-arvo-2026-annual-meeting) — Source: Oculis
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)